28th Feb 2007 17:43
Notification of major interests in shares
28 February 2007
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification State Yes/No An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Yes Other (please specify): 3. Full name of person(s) subject to the notification obligation: FMR Corp 4. Full name of shareholder(s) (if different from 3.): See attached schedule
5. Date of the transaction (and date on which the threshold is Revised due crossed
to DTR rules or reached if different): 6. Date on which issuer notified: 27 February 2007 7. Threshold(s) that is/are crossed or reached: 8. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous Resulting situation after the triggering
shares to transaction if possible the Triggering using the ISIN transaction
CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect
GB00B0KQX869 7,182,654 7,182,654 7,182,654 1.40%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted Total (A+B) Number of voting rights % of voting rights 7,182,654 1.40%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
See attached schedule Proxy Voting:10. Name of the proxy holder: FMR Corp
11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting N/A
rights: 13. Additional information: As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in the shares of FMR Corp (FMR) and Fidelity International Limited (FIL) together for the purposes of shareholder reporting. According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FIL. Please note these holdings are correct as of close of business 26 February 2007. 14. Contact name: Sophie Hughes
15. Contact telephone number: 01737 836713
(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)
Schedule:
Shares Held Nominee Management Company
684,720 STATE STREET BANK AND TR CO FMTC
128,400 STATE STREET BANK AND TR CO FMRCO
22,980 STATE STREET BANK AND TR CO FMR
82,254 STATE STREET BANK AND TR CO FICL
14,400 NORTHERN TRUST LONDON FMRCO
89,400 NORTHERN TRUST CO FMTC
37,700 MELLON BANK N.A. FMTC
53,400 MELLON BANK N.A. FMRCO
65,800 JPMORGAN CHASE BANK FPM
81,600 JPMORGAN CHASE BANK FMTC
2,309,600 JPMORGAN CHASE BANK FMRCO
3,474,800 BROWN BROTHERS HARRIMAN AND CO FMRCO
29,600 BANK OF NEW YORK FMRCO
108,000 BANK OF NEW YORK FMTC
FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts.
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire